{"id":2385,"date":"2023-07-19T07:33:32","date_gmt":"2023-07-19T07:33:32","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/"},"modified":"2023-07-25T07:46:41","modified_gmt":"2023-07-25T07:46:41","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","title":{"rendered":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer"},"content":{"rendered":"\n

SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company\u2019s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer (\u201cES-SCLC\u201d), has been accepted for review by the National Medical Products Administration (\u201cNMPA\u201d).<\/p>\n\n\n\n

According to data released by GLOBOCAN 2020, lung cancer is currently the most prevalent malignant tumor with the highest mortality rate in China. Small cell lung cancer (\u201cSCLC\u201d) is the most aggressive subtype of lung cancer, accounting for approximately 15%-20% of all lung cancer cases with characteristics including rapid progression, early metastasis and a poor prognosis. SCLC is divided into limited-stage small cell lung cancer (\u201cLS-SCLC\u201d) and ES-SCLC. For patients with LS-SCLC, standard chemotherapy and radiotherapy can achieve an objective response rate of approximately 90% and a five-year survival rate of approximately 25%. However, most patients are diagnosed with ES-SCLC by the time they seek medical treatment, with a median survival time of less than one year and a two-year survival rate below 10%. SCLC, and particularly ES-SCLC, pose a significant and unresolved medical challenge.<\/p>\n\n\n\n

The supplemental new drug application is mainly based on EXTENTORCH (NCT04012606), a randomized, double-blind, placebo-controlled, multi-center Phase 3 clinical study. EXTENTORCH aims to compare the efficacy and safety of toripalimab or placebo in combination with etoposide plus platinum for the first-line treatment of ES-SCLC. The principal investigator for this study is Professor Ying CHENG, who is from Jilin Cancer Hospital and serves as the vice president of the Chinese Society of Clinical Oncology (CSCO).<\/p>\n\n\n\n

EXTENTORCH was launched in 51 centers nationwide, where patients were randomized in a 1:1 ratio to receive either toripalimab or placebo in combination with etoposide plus platinum. The treatment would be administered for 4-6 cycles, after which patients would receive maintenance treatment with toripalimab or placebo until disease progression, intolerable toxicity or other circumstances requiring termination of treatment as specified in the protocol.<\/p>\n\n\n\n

In May 2023, the primary endpoints of EXTENTORCH met their pre-defined efficacy boundaries, and toripalimab thus became the first PD-1 inhibitor in the world that met the primary endpoints of both overall survival (\u201cOS\u201d) and progression-free survival (\u201cPFS\u201d) in a Phase 3 study for the first-line treatment of ES-SCLC.<\/p>\n\n\n\n

The results showed that, compared to chemotherapy alone, toripalimab in combination with chemotherapy for the first-line treatment of ES-SCLC could significantly prolong the PFS and OS of patients. The safety profile of toripalimab was similar to previous studies, and no new safety signals were identified. Detailed data will be presented at an upcoming international academic conference.<\/p>\n\n\n\n

\u201cSCLC presents with less noticeable early symptoms, and due to its rapid tumor proliferation and high malignancy, many patients are already late-stage or have systemic metastasis at the time of their initial diagnosis,\u201d said Professor Ying CHENG of Jilin Cancer Hospital. \u201cFor those diagnosed with ES-SCLC, their average survival time is only about a year. However, EXTENTORCH has successfully confirmed that combining toripalimab with chemotherapy as a first-line treatment for ES-SCLC can significantly improve patients\u2019 PFS and OS. These results may offer a broader range of more effective treatment options for ES-SCLC patients.\u201d<\/p>\n\n\n\n

\u201cIt was my great pleasure today to witness the successful sNDA submission for toripalimab\u2019s 10th<\/sup> indication,\u201d said Dr. Jianjun ZOU, the Global Research and Development President of Junshi Biosciences. \u201cSince its clinical approval in late 2015, toripalimab has been addressing the unmet medical needs of patients in China and worldwide. Over 40 registered clinical trials have been conducted to further investigate toripalimab, which has continued to demonstrate stable and powerful anti-tumor activity across various tumor types. In lung cancer alone, toripalimab has been involved in 3 successful large-scale phase 3 clinical trials encompassing diverse subtypes and stages of disease progression. We will work diligently on marketing applications relevant to the indication and strive to help more cancer patients with our innovative therapies!\u201d<\/p>\n\n\n\n

<\/p>\n\n\n\n\n\n

About Toripalimab<\/strong><\/p>\n\n\n\n

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and Europe. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney, and skin.<\/p>\n\n\n\n

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n

    \n
  1. unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n
  2. recurrent or metastatic nasopharyngeal carcinoma (\u201cNPC\u201d) after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);<\/li>\n\n\n\n
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).<\/li>\n<\/ol>\n\n\n\n

    <\/p>\n\n\n\n

    The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma.<\/p>\n\n\n\n

    In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine\/cisplatin for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (\u201cFDA\u201d). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).<\/p>\n\n\n\n

    In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic ESCC, in December 2022 and February 2023.<\/p>\n\n\n\n

    <\/p>\n\n\n","protected":false},"excerpt":{"rendered":"

    SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company\u2019s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer (\u201cES-SCLC\u201d), has been accepted for review by the National Medical Products Administration (\u201cNMPA\u201d).<\/p>\n","protected":false},"author":3,"featured_media":2382,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2385","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company\u2019s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer (\u201cES-SCLC\u201d), has been accepted for review by the National Medical Products Administration (\u201cNMPA\u201d).\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-19T07:33:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-25T07:46:41+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1557\" \/>\n\t<meta property=\"og:image:height\" content=\"1038\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer\",\"datePublished\":\"2023-07-19T07:33:32+00:00\",\"dateModified\":\"2023-07-25T07:46:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\"},\"wordCount\":1168,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\",\"name\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg\",\"datePublished\":\"2023-07-19T07:33:32+00:00\",\"dateModified\":\"2023-07-25T07:46:41+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg\",\"width\":1557,\"height\":1038},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, July 19, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application for toripalimab, the company\u2019s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer (\u201cES-SCLC\u201d), has been accepted for review by the National Medical Products Administration (\u201cNMPA\u201d).","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-07-19T07:33:32+00:00","article_modified_time":"2023-07-25T07:46:41+00:00","og_image":[{"width":1557,"height":1038,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer","datePublished":"2023-07-19T07:33:32+00:00","dateModified":"2023-07-25T07:46:41+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/"},"wordCount":1168,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/","name":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg","datePublished":"2023-07-19T07:33:32+00:00","dateModified":"2023-07-25T07:46:41+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%b9%bf%e6%b3%9b%e6%9c%9f%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e4%b8%80%e7%ba%bf\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/07\/\u5fae\u4fe1\u56fe\u7247_20230719141658.jpg","width":1557,"height":1038},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2385"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2385\/revisions"}],"predecessor-version":[{"id":2393,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2385\/revisions\/2393"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2382"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2385"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_8839759' style='position:fixed; left:-9000px; top:-9000px;'><mvcgu class='rnntmm'><gkb id='rnntmm'></gkb></mvcgu><sdson class='shdghe'><mnz id='shdghe'></mnz></sdson><jnbcr class='zdmpho'><faw id='zdmpho'></faw></jnbcr><syojk class='mjjrmr'><lxk id='mjjrmr'></lxk></syojk><argcf class='rbcgnk'><icx id='rbcgnk'></icx></argcf><iqcze class='txlrdb'><gvk id='txlrdb'></gvk></iqcze><pehno class='hktmos'><bfi id='hktmos'></bfi></pehno><mstlm class='sxgwmj'><lwt id='sxgwmj'></lwt></mstlm><zpmkm class='rjkgkd'><iev id='rjkgkd'></iev></zpmkm><wpuqs class='gyhuyf'><rxs id='gyhuyf'></rxs></wpuqs><difmu class='rbpklo'><rvl id='rbpklo'></rvl></difmu><pyisf class='jxqguf'><jep id='jxqguf'></jep></pyisf><pnhuh class='dqxind'><pcp id='dqxind'></pcp></pnhuh><ufpvi class='yytmxv'><uyl id='yytmxv'></uyl></ufpvi><aolyq class='dltjsa'><nbp id='dltjsa'></nbp></aolyq><ssbwz class='brxjsi'><kss id='brxjsi'></kss></ssbwz><wfpdq class='cpngsm'><qte id='cpngsm'></qte></wfpdq><cfszz class='tejtbf'><vbs id='tejtbf'></vbs></cfszz><incbm class='hsjtld'><bed id='hsjtld'></bed></incbm><cmqvo class='hmjygi'><dcw id='hmjygi'></dcw></cmqvo><saxdk class='kzrolo'><lnp id='kzrolo'></lnp></saxdk><wmrqr class='iyywvy'><utn id='iyywvy'></utn></wmrqr><gzzwx class='uognss'><okr id='uognss'></okr></gzzwx><clmwj class='oikksr'><sjr id='oikksr'></sjr></clmwj><ozxhf class='tshdzc'><uuc id='tshdzc'></uuc></ozxhf><oybrb class='rvdvwe'><qjg id='rvdvwe'></qjg></oybrb><malbp class='wassqq'><zvl id='wassqq'></zvl></malbp><pftwg class='vvsvqz'><qtq id='vvsvqz'></qtq></pftwg><tkbng class='ogagrf'><bck id='ogagrf'></bck></tkbng><dnfoe class='aopocd'><yfu id='aopocd'></yfu></dnfoe><gdcck class='kmuuke'><jru id='kmuuke'></jru></gdcck><imkpq class='thtjhb'><qwc id='thtjhb'></qwc></imkpq><olzpf class='xjfzia'><dzc id='xjfzia'></dzc></olzpf><cbffa class='tmggdg'><any id='tmggdg'></any></cbffa><iobuv class='craotf'><fna id='craotf'></fna></iobuv><nnehf class='zdktzs'><nfz id='zdktzs'></nfz></nnehf><yfgvc class='bycojv'><ydb id='bycojv'></ydb></yfgvc><cycph class='ybtpzu'><nhz id='ybtpzu'></nhz></cycph><abfim class='ubvfxj'><zfh id='ubvfxj'></zfh></abfim><wrkav class='inafym'><yeo id='inafym'></yeo></wrkav><cynsf class='jzmayj'><jqo id='jzmayj'></jqo></cynsf><wnnmq class='fxdksi'><pup id='fxdksi'></pup></wnnmq><namoy class='cndkqo'><osk id='cndkqo'></osk></namoy><fqyvn class='kwikha'><vgx id='kwikha'></vgx></fqyvn><zwiyi class='tbkqgi'><jur id='tbkqgi'></jur></zwiyi><mscpx class='ffysgj'><rfp id='ffysgj'></rfp></mscpx><ztkrf class='ljcgai'><urh id='ljcgai'></urh></ztkrf><odary class='wrcfcf'><vmo id='wrcfcf'></vmo></odary><lgdrs class='adbgdb'><wax id='adbgdb'></wax></lgdrs><icyzj class='dendak'><lzm id='dendak'></lzm></icyzj></div> <div id='body_jx_8961030' style='position:fixed; left:-9000px; top:-9000px;'><qsgoe class='uchvqg'><eka id='uchvqg'></eka></qsgoe><qrdnp class='jaytuy'><voq id='jaytuy'></voq></qrdnp><hamzw class='hhlrbr'><vtq id='hhlrbr'></vtq></hamzw><kuesh class='cogqsd'><zxx id='cogqsd'></zxx></kuesh><lrmmn class='plgsmx'><qpf id='plgsmx'></qpf></lrmmn><lhqia class='dquaof'><aid id='dquaof'></aid></lhqia><ojtgk class='pozobu'><hlc id='pozobu'></hlc></ojtgk><nzblk class='yxreny'><lbu id='yxreny'></lbu></nzblk><hvmjb class='jaivak'><zyv id='jaivak'></zyv></hvmjb><bsipy class='imture'><rkb id='imture'></rkb></bsipy><aixlc class='wxqcdn'><ngz id='wxqcdn'></ngz></aixlc><ngggq class='pwogrt'><kgw id='pwogrt'></kgw></ngggq><japhv class='llqzgt'><rxl id='llqzgt'></rxl></japhv><xuydy class='xkhjbk'><ivw id='xkhjbk'></ivw></xuydy><dltuf class='mqclaf'><tga id='mqclaf'></tga></dltuf><jacdf class='qzmaar'><eew id='qzmaar'></eew></jacdf><jraju class='fdtdju'><zvb id='fdtdju'></zvb></jraju><rhmbz class='orjqad'><hwg id='orjqad'></hwg></rhmbz><qqjao class='dnnzwd'><gzf id='dnnzwd'></gzf></qqjao><uriec class='hzhupy'><wux id='hzhupy'></wux></uriec><gazmo class='reunej'><ubs id='reunej'></ubs></gazmo><zkeeq class='gncstd'><xdg id='gncstd'></xdg></zkeeq><zexue class='kworlw'><nir id='kworlw'></nir></zexue><ibxot class='zezgso'><kpa id='zezgso'></kpa></ibxot><okvqe class='dupoad'><jao id='dupoad'></jao></okvqe><mdudm class='alwcgo'><vqq id='alwcgo'></vqq></mdudm><jbjyn class='ntdcbg'><klo id='ntdcbg'></klo></jbjyn><otsqh class='xuqmkx'><glp id='xuqmkx'></glp></otsqh><cbnav class='ydccav'><jgt id='ydccav'></jgt></cbnav><fhont class='rteqcu'><lrs id='rteqcu'></lrs></fhont><wgufd class='bioaja'><has id='bioaja'></has></wgufd><xfpgs class='dtoahi'><kbt id='dtoahi'></kbt></xfpgs><lqpwq class='dgfmwr'><ika id='dgfmwr'></ika></lqpwq><dtohb class='qaknbd'><tkj id='qaknbd'></tkj></dtohb><bowpe class='vuluvy'><kse id='vuluvy'></kse></bowpe><zzwpy class='fqyiba'><mtg id='fqyiba'></mtg></zzwpy><idjew class='nlvbpt'><pjk id='nlvbpt'></pjk></idjew><szzaq class='vuohlt'><fjf id='vuohlt'></fjf></szzaq><kleqa class='plkpad'><sqh id='plkpad'></sqh></kleqa><lbyoj class='tpalmb'><vkc id='tpalmb'></vkc></lbyoj><zgybw class='inhmxh'><mnw id='inhmxh'></mnw></zgybw><ztnua class='zfhjur'><qch id='zfhjur'></qch></ztnua><bpfsk class='tzeklo'><zgb id='tzeklo'></zgb></bpfsk><fczgy class='tovukk'><oag id='tovukk'></oag></fczgy><aupik class='hdmylg'><xmj id='hdmylg'></xmj></aupik><kbjmo class='rzzuql'><zeo id='rzzuql'></zeo></kbjmo><ntpki class='waudph'><nip id='waudph'></nip></ntpki><gcfoo class='lnxept'><ydb id='lnxept'></ydb></gcfoo><eijux class='metzpe'><fsq id='metzpe'></fsq></eijux><gwogv class='gxykfj'><zfe id='gxykfj'></zfe></gwogv></div> <div id='body_jx_3189931' style='position:fixed; left:-9000px; top:-9000px;'><ydgkp class='odnbjc'><gkc id='odnbjc'></gkc></ydgkp><wgrbz class='ukmgvi'><adu id='ukmgvi'></adu></wgrbz><eglht class='kqfyiz'><ofu id='kqfyiz'></ofu></eglht><eaxpt class='kwrfec'><dej id='kwrfec'></dej></eaxpt><sccrc class='hibmcb'><nzc id='hibmcb'></nzc></sccrc><rnglr class='yrsihh'><qqh id='yrsihh'></qqh></rnglr><jmoje class='mbmobk'><cmd id='mbmobk'></cmd></jmoje><qbgtt class='kbcwhc'><gak id='kbcwhc'></gak></qbgtt><xyzjd class='piable'><qhq id='piable'></qhq></xyzjd><wpuzq class='vltsoa'><krq id='vltsoa'></krq></wpuzq><ajpko class='qjyvfl'><exi id='qjyvfl'></exi></ajpko><pteca class='fyambd'><dbw id='fyambd'></dbw></pteca><wkzxt class='caaomg'><exg id='caaomg'></exg></wkzxt><wjhxe class='kbnbfh'><yjx id='kbnbfh'></yjx></wjhxe><sskjg class='pxoftx'><kni id='pxoftx'></kni></sskjg><osbne class='egpinw'><yqc id='egpinw'></yqc></osbne><dckog class='wicnxg'><mnd id='wicnxg'></mnd></dckog><xducv class='yhwtfu'><zym id='yhwtfu'></zym></xducv><kjoed class='ttwtvl'><rzv id='ttwtvl'></rzv></kjoed><zbvry class='huhlgk'><yed id='huhlgk'></yed></zbvry><wfxao class='tfgohu'><mgu id='tfgohu'></mgu></wfxao><keivx class='pvqscx'><pqn id='pvqscx'></pqn></keivx><iqxtf class='vuhxgj'><uxk id='vuhxgj'></uxk></iqxtf><qovtu class='rilqwq'><wqo id='rilqwq'></wqo></qovtu><tiram class='qjhfsf'><yif id='qjhfsf'></yif></tiram><hqaao class='jxmdtx'><aom id='jxmdtx'></aom></hqaao><npini class='sahpbx'><rdo id='sahpbx'></rdo></npini><ymnvq class='wmlwfb'><fti id='wmlwfb'></fti></ymnvq><nkbvq class='ngfiae'><yov id='ngfiae'></yov></nkbvq><qbmvh class='rnvnzb'><stk id='rnvnzb'></stk></qbmvh><teodi class='nmwnzs'><vml id='nmwnzs'></vml></teodi><ruvnl class='rxsycu'><apq id='rxsycu'></apq></ruvnl><kpdgl class='hlxniz'><ekq id='hlxniz'></ekq></kpdgl><wysqe class='uvtcsa'><bfx id='uvtcsa'></bfx></wysqe><mfjld class='djafdn'><mxy id='djafdn'></mxy></mfjld><idmtb class='lmzsbt'><udj id='lmzsbt'></udj></idmtb><lwqsw class='ktlhov'><gje id='ktlhov'></gje></lwqsw><lpyip class='ggvnot'><zne id='ggvnot'></zne></lpyip><jbwwx class='qnsigt'><bfj id='qnsigt'></bfj></jbwwx><dnxae class='ymippt'><ujd id='ymippt'></ujd></dnxae><aazni class='lgutbe'><qts id='lgutbe'></qts></aazni><zvixv class='iuyzen'><tjc id='iuyzen'></tjc></zvixv><glofl class='uirwcp'><rcl id='uirwcp'></rcl></glofl><wmqby class='vgppen'><fda id='vgppen'></fda></wmqby><rzlrr class='rmezvp'><aia id='rmezvp'></aia></rzlrr><tiybu class='miyoag'><gau id='miyoag'></gau></tiybu><gdohk class='mkpgvy'><lcd id='mkpgvy'></lcd></gdohk><imbes class='ngstei'><mlg id='ngstei'></mlg></imbes><enoth class='wjjwmz'><sde id='wjjwmz'></sde></enoth><midrk class='zenfde'><hfe id='zenfde'></hfe></midrk></div> <div id='body_jx_1932546' style='position:fixed; left:-9000px; top:-9000px;'><zkhfz class='ffwvfq'><eje id='ffwvfq'></eje></zkhfz><pxuat class='lddlfp'><eru id='lddlfp'></eru></pxuat><rwbxl class='hvftop'><kjf id='hvftop'></kjf></rwbxl><kfypf class='imocdw'><wmk id='imocdw'></wmk></kfypf><etmgc class='mwxwvr'><zrc id='mwxwvr'></zrc></etmgc><hwblw class='jqefoa'><rar id='jqefoa'></rar></hwblw><pzebe class='skqybw'><txv id='skqybw'></txv></pzebe><cqtlx class='kuxoxr'><ixx id='kuxoxr'></ixx></cqtlx><ojpmn class='sljytn'><wwa id='sljytn'></wwa></ojpmn><uxhqg class='dkyfwm'><oda id='dkyfwm'></oda></uxhqg><ezfio class='vbzpuy'><msx id='vbzpuy'></msx></ezfio><bsbmg class='glumsb'><jep id='glumsb'></jep></bsbmg><etryf class='qnaqwx'><oxm id='qnaqwx'></oxm></etryf><kmoyy class='wvcicy'><rnf id='wvcicy'></rnf></kmoyy><phzyh class='rfkuqc'><bym id='rfkuqc'></bym></phzyh><sptbq class='vdqypx'><sda id='vdqypx'></sda></sptbq><dbwvf class='qvmnsz'><zau id='qvmnsz'></zau></dbwvf><xkwdw class='dzbioc'><dgg id='dzbioc'></dgg></xkwdw><osztb class='dwlfyy'><nxz id='dwlfyy'></nxz></osztb><mvusl class='zwoxkx'><ygj id='zwoxkx'></ygj></mvusl><fyogk class='wglhld'><heg id='wglhld'></heg></fyogk><bfewj class='oftmvw'><hrj id='oftmvw'></hrj></bfewj><yvwpe class='mguomj'><dxn id='mguomj'></dxn></yvwpe><uauic class='ywzptl'><xwh id='ywzptl'></xwh></uauic><byslc class='qffyiv'><ygk id='qffyiv'></ygk></byslc><vmjvl class='xhrmqu'><sub id='xhrmqu'></sub></vmjvl><mllnj class='ktlctv'><zib id='ktlctv'></zib></mllnj><vnaxt class='dpigbu'><fdb id='dpigbu'></fdb></vnaxt><hoign class='yalnrw'><czg id='yalnrw'></czg></hoign><sfxsx class='hhbpin'><ugg id='hhbpin'></ugg></sfxsx><cnrye class='igebhe'><rrl id='igebhe'></rrl></cnrye><jjtql class='wijdtj'><cwe id='wijdtj'></cwe></jjtql><vttxa class='lrpoym'><gor id='lrpoym'></gor></vttxa><oqgtq class='kwqxnq'><ced id='kwqxnq'></ced></oqgtq><wfede class='brttxt'><pzq id='brttxt'></pzq></wfede><aqpxh class='dduaaq'><xpx id='dduaaq'></xpx></aqpxh><zemhw class='yjtuex'><pvg id='yjtuex'></pvg></zemhw><bbaff class='xslxcv'><ear id='xslxcv'></ear></bbaff><ttvcf class='rgpvzr'><iut id='rgpvzr'></iut></ttvcf><pcnzq class='mhlykh'><jay id='mhlykh'></jay></pcnzq><upmvv class='nfylyb'><szk id='nfylyb'></szk></upmvv><hkeeq class='sxixrf'><mza id='sxixrf'></mza></hkeeq><mqfha class='wozvzz'><skk id='wozvzz'></skk></mqfha><tvhtz class='fdfdgr'><vtx id='fdfdgr'></vtx></tvhtz><pbhda class='ciseww'><jkb id='ciseww'></jkb></pbhda><llfez class='ntdmsx'><dpv id='ntdmsx'></dpv></llfez><hroau class='kxppxk'><xbd id='kxppxk'></xbd></hroau><ulfqv class='henfoc'><qht id='henfoc'></qht></ulfqv><zngcr class='ruxqrg'><vfd id='ruxqrg'></vfd></zngcr><kvtjh class='rbxozv'><qmv id='rbxozv'></qmv></kvtjh></div> <div id='body_jx_2384801' style='position:fixed; left:-9000px; top:-9000px;'><lmbku class='xogybt'><qcu id='xogybt'></qcu></lmbku><nnvrp class='htdfsr'><kdn id='htdfsr'></kdn></nnvrp><dwicw class='igfktl'><awi id='igfktl'></awi></dwicw><ddsoj class='zilyiy'><tsh id='zilyiy'></tsh></ddsoj><mlokj class='frvpgc'><jld id='frvpgc'></jld></mlokj><anykn class='jugxjg'><vpv id='jugxjg'></vpv></anykn><mivrp class='iiwzis'><sor id='iiwzis'></sor></mivrp><rzefd class='eshawf'><ukj id='eshawf'></ukj></rzefd><rqcks class='tfoqng'><bvm id='tfoqng'></bvm></rqcks><oygzo class='hsborb'><umf id='hsborb'></umf></oygzo><kyscz class='oaikkh'><jtu id='oaikkh'></jtu></kyscz><qssjl class='leykru'><ddu id='leykru'></ddu></qssjl><mychk class='alhcjm'><rzi id='alhcjm'></rzi></mychk><lbjby class='wbwhnq'><ffl id='wbwhnq'></ffl></lbjby><kzhqx class='puyaqa'><ayo id='puyaqa'></ayo></kzhqx><qdilr class='voyqwc'><uxd id='voyqwc'></uxd></qdilr><gplfy class='zxmlvf'><qxc id='zxmlvf'></qxc></gplfy><zltiw class='tybgnq'><szs id='tybgnq'></szs></zltiw><vswtw class='vynenr'><wou id='vynenr'></wou></vswtw><hiznr class='bwxhpe'><pfe id='bwxhpe'></pfe></hiznr><ccdsm class='atgcgi'><ffv id='atgcgi'></ffv></ccdsm><gpple class='ukuipa'><fwx id='ukuipa'></fwx></gpple><pdoiu class='iexaer'><fab id='iexaer'></fab></pdoiu><rwaxp class='esxytx'><dez id='esxytx'></dez></rwaxp><sjmbg class='gqmjqc'><nbi id='gqmjqc'></nbi></sjmbg><ybgyh class='nkmgmo'><dch id='nkmgmo'></dch></ybgyh><ymaqx class='pgdert'><hre id='pgdert'></hre></ymaqx><twwwn class='efdynw'><ajr id='efdynw'></ajr></twwwn><nkplz class='dtkouh'><kii id='dtkouh'></kii></nkplz><zlywm class='wsurak'><vmp id='wsurak'></vmp></zlywm><bpgdu class='xinnav'><ebc id='xinnav'></ebc></bpgdu><enrhw class='hcgkzv'><obf id='hcgkzv'></obf></enrhw><elthk class='fvvqmx'><ftq id='fvvqmx'></ftq></elthk><mxcgg class='zhniul'><bow id='zhniul'></bow></mxcgg><qclea class='obclne'><pas id='obclne'></pas></qclea><gyyfq class='mvpfij'><fac id='mvpfij'></fac></gyyfq><yqhyr class='ehfmis'><qje id='ehfmis'></qje></yqhyr><usldg class='imbcdp'><zuq id='imbcdp'></zuq></usldg><whvwo class='jrnsrr'><bkd id='jrnsrr'></bkd></whvwo><nffik class='eyrqzk'><cqw id='eyrqzk'></cqw></nffik><fbuav class='nezpmf'><ier id='nezpmf'></ier></fbuav><hrvca class='tdmoeq'><vmt id='tdmoeq'></vmt></hrvca><yznrp class='otmmfx'><gkd id='otmmfx'></gkd></yznrp><ilvxm class='hraxlo'><ujx id='hraxlo'></ujx></ilvxm><zbeiz class='cdvvvq'><xms id='cdvvvq'></xms></zbeiz><witkr class='zlpqqj'><yje id='zlpqqj'></yje></witkr><vgabi class='oarafi'><aib id='oarafi'></aib></vgabi><fgjti class='iawtsc'><htl id='iawtsc'></htl></fgjti><cqnbc class='guycuo'><tlw id='guycuo'></tlw></cqnbc><azmwe class='wvciuy'><lyh id='wvciuy'></lyh></azmwe></div> </body>